Eli Lilly Receives EMA CHMP Positive Opinion Recommending Marketing Authorization For Foundayo For Treatment Of Type 2 Diabetes Mellitus And For Weight Management
https://www.ema.europa.eu/en/medicines/human/EPAR/foundayo
Share
Why It Matters
Eli Lilly's new diabetes and weight loss medicine got a big approval step in Europe. This suggests the company's product pipeline is working, which investors watch closely.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.